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In order to determine the performance, and
particularly the sensitivity and speciﬁcity, of the
Focus HSV-2 ELISA in Chinese STD settings, 105
serum specimens were collected from patients
attending the STD Clinic of the Chinese Academy
of Medical Sciences, and the Peking Union Med-
ical College Institute of Dermatology. The results
obtained with the Focus HSV-2 ELISA were
compared with those determined by the Western
blot method.
The seroprevalence of HSV-2, as determined by
Western blot, was 55.2% (58 ⁄ 105 specimens) in
the study population. The Focus HSV-2 ELISA
and Western blot results were concordant (both
negative or both positive) for 89.5% of the 105
specimens, with 92.0% sensitivity and 95.7%
speciﬁcity, and positive and negative predictive
values of 95.8% and 91.7%, respectively, if spec-
imens with equivocal ELISA results were exclu-
ded from the calculation. The sensitivity and
speciﬁcity were 79.3% and 95.7%, respectively, if
the samples with equivocal ELISA results were
considered negative, and were 93.1% and 93.6%,
respectively, if the samples with equivocal ELISA
results were considered positive. Analysis with a
receiver operator characteristic curve demonstra-
ted that the best index cut-off value to optimise
the assay performance in this population was 0.9,
with a sensitivity of 93.1% (95% CI, 83.3–98.0%)
and a speciﬁcity of 93.6% (95% CI, 82.4–98.6%).
If the manufacturer’s recommended index cut-off
value of 1.1 was used, the sensitivity was only
79.3%.
In summary, the sensitivity and speciﬁcity of
the Focus HSV-2 ELISA in a Chinese STD popu-
lation were satisfactory but, compared with other
countries, a lower index cut-off value might be
required for optimal sensitivity and speciﬁcity.
Y.-P. Yin, X.-S. Chen*,
B. Song, X. Yao,
Z.-J. Hu and W.-Z. Li
National Center for STD Prevention and Control,
Chinese Academy of Medical Sciences
& Peking Union Medical College Institute
of Dermatology,
12 Jiangwangmiao Street,
Nanjing,
Jiangsu 210042,
China
*E-mail: chenxs@vip.163.com
ACKNOWLEDGEMENT
This study was supported by the National Natural Science
Foundation of China (grant no. 30170857).
REFERENCE
1. Ashley-Morrow R, Nollkamper J, Robinson NJ, Bishop N,
Smith J. Performance of Focus ELISA tests for herpes sim-
plex virus type 1 (HSV-1) and HSV-2 antibodies among
women in ten diverse geographical locations. Clin Microbiol
Infect 2004; 10: 530–536.
10.1111/j.1469-0691.2005.01115.x
Immunisation against tick-borne
encephalitis by widely used vaccines:
short-term history and current
recommendations
Tick-borne encephalitis (TBE) virus, transmitted
by ticks, remains a serious health problem in
central ⁄ eastern Europe and Asia. TBE virus is a
member of the Flavivirus family. The biology of
the main vector ticks, Ixodes ricinus and Ixodes
persulcatus, is understood in so far as it is clinically
relevant [1]. In the recent article by Charrel et al.
[2], the authors state that vaccination is the most
important means of prevention of TBE. In this
context, the authors provide an overview of
available TBE vaccines. However, the data provi-
ded do not include important information regard-
ing recent TBE vaccine developments and
discussions on TBE immunisation schedules for
primary and booster immunisation.
Two commercially available vaccines and their
formulations are currently used widely in central
and eastern Europe, namely new versions of
Encepur (Chiron Vaccines, Marburg, Germany)
and FSME-IMMUN (Baxter Vaccines, Vienna,
Austria) (Table 1). The development of an inacti-
vated vaccine was initiated in 1971. Various
versions of this ﬁrst TBE vaccine (FSME-IMMUN)
have been approved since 1976. In 1999, the
preservative thiomersal was removed, and a new
formulation, free of thiomersal and human serum
albumin (TicoVac), was introduced in 2000. How-
ever, an increased rate of reported cases of
high fever and febrile convulsions in children
was noted. Human albumin was subsequently
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re-introduced into the vaccine formulation in
2001, with a resulting dramatic reduction in
reports of adverse events with this amended
formulation (FSME-IMMUN new) compared to
TicoVac [3]. A paediatric formulation is available
with half the antigen dose in a 0.25-mL volume
(FSME-IMMUN Junior) [4].
The ﬁrst TBE vaccine speciﬁcally for children,
Encepur K, was licensed in 1994 in Germany, with
a reduced antigen content compared with the
preparation for adults. Although very rare, a
number of children had allergic reactions, prob-
ably caused by the polygeline content [5]. There-
fore, polygeline was removed from the vaccine,
and improved and polygeline-free TBE formula-
tions were developed, namely Encepur Adults
(0.5 mL), licensed for use in individuals aged
> 12 years, containing 1.5 lg of inactivated TBE
virus antigen (strain K 23), and Encepur Children
(0.25 mL), containing 0.75 lg of inactivated TBE
virus antigen [5]. TBE vaccines from both the
above manufacturers can be considered safe and
highly protective [3–5], and the conventional
vaccination schedule for both vaccines comprises
three doses at day 0, months 1–3 and months 9–12
(or 5–12 months after the second dose).
Accelerated immunisation schedules have also
been described for both vaccines. A rapid immu-
nisation schedule comprising three doses at days
0, 7 and 21 has been licensed for the historical and
current versions of Encepur Adults and Encepur
Children. Protective TBE antibodies can be meas-
ured 2 weeks after the second dose, and protect-
ive immunity can be attained for at least one TBE
season [6,7]. Thus, this immunisation schedule is
recommended when offering TBE prophylaxis at
short notice, e.g., for individuals travelling to
endemic TBE areas, or when the tick season
has already started [8]. The ﬁrst booster dose
should be given after 12–18 months if long-term
protection is required [8]. The accelerated regi-
men for the FSME-IMMUN formulations (Inject,
Adult, Junior) comprises two vaccine doses given
2–3 weeks apart (licensed for the Czech Republic,
Austria and Germany) [9,10]. Fourteen days after
the second dose, 92.9% of subjects already have
ELISA values of > 126 VIE U (Vienna units) ⁄mL,
increasing to 96.4% and 98.2% at days 21 and 42,
respectively, after the second dose of vaccine [10].
However, no clear information regarding the
duration of protective immunity is available.
Formerly, booster doses were recommended at
3-year intervals. However, recent studies have
questioned the necessity of such short booster
intervals [7,11,12]. As a result, the Austrian
immunisation board now recommends a ﬁrst
booster dose at 3 years after primary immunisa-
tion, with subsequent boosters every 5 years for
individuals aged < 60 years, but every 3 years for
individuals aged > 60 years [9]. When using the
rapid immunisation schedule (three doses at days
0, 7 and 21), the ﬁrst booster dose is recommen-
ded after 12–18 months. Subsequent boosters
should be given every 5 years for individuals
aged < 60 years, but every 3 years for individuals
aged > 60 years [8].
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Table 1. Different formulations of
the FSME-IMMUN and ENCEPUR
vaccines
FSME-IMMUN
Inject s (1999)a
FSME-IMMUN
0.5 Adult
(since 2001)
Encepur Adults
(since 2001)
FSME-IMMUN
0.25 Junior
Encepur
Children
Strain Neudoerﬂ Neudoerﬂ K-23 Neudoerﬂ K-23
Passages PCECb PCEC PCEC PCEC PCEC
Production PCEC PCEC PCEC PCEC PCEC
Amount of
antigen
2–3.5 lg 2.4 lg 1.5 lg 1.2 lg 0.75 lg
Adjuvant Al(OH)3 Al(OH)3 Al(OH)3 Al(OH)3 Al(OH)3
Preservative No No No No No
Stabiliser HSA HSA No additional HSA No additional
Age limitations > 1 year > 16 years ‡ 12 years £ 16 years < 12 years
Shelf-life 18 months 18 months 24 months 18 months 24 months
Adjusted 0.5 mL 0.5 mL 0.5 mL 0.25 mL 0.25 mL
HSA, human serum albumin; PCEC, puriﬁed chicken embryo cells.
aAvailable in the Czech Republic, Hungary, Russia and the Baltic states.
bPassages of master seed have been done on mouse brain.
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